Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability

Cardiovascular Research

Volumn 47, Issue 4, 2000, Pages 648-657

  Koh, Kwang Kon ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Endothelial function; Infection inflammation; Statins

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; FARNESOL; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MEVALONIC ACID; NITRIC OXIDE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTILIPEMIC AGENTS; CELL DIVISION; CELL MOVEMENT; CHOLESTEROL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MACROPHAGES; MATRIX METALLOPROTEINASES; MUSCLE, SMOOTH, VASCULAR; VASODILATOR AGENTS;

EID: 0001539238     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00146-2     Document Type: Review

References (104)

1. Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med. 340:1999;115-126.
2. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 344:1994;1383-1389.
3. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 335:1996;1001-1009.
4. Shepherd J., Cobbe S.M., Ford I., et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc. 279:1998;1615-1622.
6. Jukema J.W., Bruschke A.V.G., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and broad range of initial cholesterol levels. New Engl J Med. 339:1998;1349-1357.
8. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Expert Panel Report of the National Cholesterol Education Program, Arch Intern Med 1986;148:36-9.
9. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015-23.
10. Pekkannen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New Engl J Med. 322:1990;1700-1707.
11. Grover S.A., Coupal L., Hu X.P. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? J Am Med Assoc. 274:1995;801-806.
12. Bellosta S., Bernini F., Ferri N., Quarato P., Canavesi M., Arnaboldi L., et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 137:1998;S101-S109.
13. Bernini F., Didoni G., Bonfadini G., Bellosta S., Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 104:1993;19-26.
14. Corsini A., Mazzotti M., Raiteri M., et al. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 101:1993;117-125.
15. Brown M.S., Goldstein J.L. Mad bet for Rab. Nature. 366:1993;14-15.
16. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., et al. CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 13:1993;571-578.
17. Raiteri M., Arnaboldi L., McGeady P., Gelb M.H., Verri D., Talgiabue C., et al. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther. 281:1997;1144-1153.
18. Stark W.W. Jr., Blaskovich M.A., Johnson B.A., Qian Y., Vasudevan A., Pitt B., et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 275:1998;L55-L63.
19. kip1. J Biol Chem. 274:1999;21926-21931.
20. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than lower cholesterol. Lancet. 348:1996;1079-1082.
21. Kinlay S., Selwyn A.P., Delagrange D., Creager M.A., Libby P., Ganz P., et al. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end points. Curr Opin Lipidol. 7:1996;389-397.
22. Ludmer P.L., Selwyn A.A., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. New Engl J Med. 315:1986;1046-1051.
23. Egashira K., Inou T., Hirooka Y., Yamada A., Maruoka Y., Kai H., et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 91:1993;29-37.
24. Quyyumi A.A., Dakak N., Mulcahy D., Andrews N.P., Husain S., Panza J.A., et al. NO activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol. 29:1997;308-317.
25. Casino P.R., Kilcoyne C.M., Quyyumi A.A., Hoeg J.M., Panza J.A. Role of NO in the endothelium-dependent vasodilation in hypercholesterolemic patients. Circulation. 88:1993;2541-2547.
26. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 12:1988;56-62.
27. Little W.C., Constantinescu M., Applegate R.J., et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 78:1988;1157-1166.
28. Nakagomi A., Celermajer D.S., Lumley T., Freedman S.B. Angiographic severity of coronary narrowing is a surrogate marker of the extent of coronary atherosclerosis. Am. J. Cardiol. 78:1996;516-519.
29. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases superoxide anion production. J. Clin. Invest. 91:1993;2546-2551.
30. 2α, in experimental hypercholesterolemia. Cardiovasc. Res. 44:1999;601-607.
31. Minor R.L., Myers P.R., Guerra R., Bates J.N., Harrison D.G. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J. Clin. Invest. 86:1990;2109-2116.
32. Pritchard K.A. Jr., Groszek L., Smalley D.M., Sessa W.C., Wu M., Villalon P., et al. Native low-density lipoprotein increases endothelial cell NO synthase generation of superoxide anion. Circ. Res. 77:1995;510-518.
33. Mohan P.F., Desaiah D. Very low density and low density lipoproteins induce nitric oxide synthesis in macrophages. Biochem. Biophys. Res. Commun. 204:1994;1047-1054.
34. Hirata K., Miki N., Kuroda Y., Sakoda T., Kawashima S., Yokoyama M., et al. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive NO synthase mRNA expression in bovine aortic endothelial cells. Circ. Res. 76:1995;958-962.
35. Dulak J., Polus M., Guevara I., Hartwich J., Wybranska I., Krzesz R., et al. Oxidized low density lipoprotein inhibits inducible NO synthase, GTP cyclohydrolase I and transforming growth factor beta gene expression in rat macrophages. J. Physiol. Pharmacol. 50:1999;429-441.
36. Yang X., Cai B., Sciacca R.R., Cannon P.J. Inhibition of inducible NO synthase in macrophages by oxidized low-density lipoproteins. Circ. Res. 74:1994;318-328.
37. Buttery L.D., Springall D.R., Chester A.H., Evans T.J., Standfield E.N., Parums D.V., et al. Inducible NO synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab. Invest. 75:1996;77-85.
38. Gordon J.B., Ganz P., Nabel E.G., Fish R.D., Zebede J., Mudge G.H., et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J. Clin. Invest. 83:1989;1946-1952.
39. Cardillo C., Kilcoyne C.M., Quyyumi A.A., Cannon R.O. III, Panza J.A. Role of NO in the vasodilator response to mental stress in normal subjects. Am. J. Cardiol. 80:1997;1070-1074.
40. Cayette A.J., Palacino J.J., Horten K., Cohen R.A. Chronic inhibition of NO production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 14:1994;753-759.
41. Hamon M., Vallet B., Bauters C., Wernert N., McFadden E.P., Lablanche J.-M., et al. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation. 90:1994;1357-1362.
42. Fuster V, Badimon L et al., The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992;326:242-50, 310-8.
43. Tillett H.E., Smith J.W., Gooch C.D. Excess deaths attributable to influenza in England and Wales: age at death and certified cause. Int. J. Epidemiol. 12:1983;344-352.
44. Valtonen V., Kuikka A., Syrjanen J. Thrombo-embolic complications in bacteraemic infections. Eur. Heart J. 14:(Suppl K):1993;20-23.
45. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. New Engl. J. Med. 331:1994;417-424.
46. Kanda T., Hirao Y., Oshima S., et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am. J. Cardiol. 77:1996;304-307.
47. Gates P., Marwood S., Jelinek M., Scott M. Unreported symptomatic and asymptomatic ischaemic heart disease in patients presenting with TIA or minor stroke detected by the London School of Hygiene Cardiovascular Questionnaire and Minnesota coding of a routine ECG. Clin. Exp. Neurol. 24:1987;21-25.
48. Wang P., Ba Z.F., Chaudry I.H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am. J. Physiol. 266:1994;H2535-H2541.
49. Bhagat K., Moss R., Collier J., Vallance P. Endothelial stunning following a brief exposure to endotoxin-a mechanism to link infection and infarction. Cardiovasc. Res. 32:1996;822-829.
50. Gupta S., Leatham E.W., Carrington D., et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407.
51. Ridker P.M., Kundsin R.B., Stampfer M.J., Poulin S., Hennekens C.H. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 99:1999;1161-1164.
52. Ridker P.M., Hennekens C.H., Stampfer M.J., Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and risks of future myocardial infarction and stroke. Circulation. 98:1998;2796-2799.
53. Anderson J.L., Muhlestein J.B., Carlquist J., Allen A., Trehan S., Nielson C., et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for infection. The azithromycin in coronary artery disease:elimination of myocardial infection with Chlamydia (ACADEMIC) Study. Circulation. 99:1999;1540-1547.
54. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent vasomotion. New Engl. J. Med. 332:1995;488-493.
55. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillablower M.E., Kosinski A.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl. J. Med. 332:1995;481-487.
56. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
57. van Boven A.J., Jukema J.W., Zwinderman A.H., Crijns H.J., Lie K.I., Bruschke A.V.G., et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
58. Aengevaeren W.R.M., Uijen G.J.H., Jukema J.W., Bruschke A.V.G., Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study. Circulation. 96:1997;429-435.
59. Goode G.K., Heagerty A.M. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation. 91:1995;2898-2903.
60. Koh K.K., Cardillo C., Bui M.N., Hathaway L., Csako G., Waclawiw M.A., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 99:1999;354-360.
61. John S., Schlaich M.S., Langenfeld M., Weihprecht H., Schmitz G., Weidinger G., et al. Increased bioavailability of NO after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 98:1998;211-216.
62. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Tsutomu I., et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
63. Wennmalm A., Benthin G., Edlund A., et al. Metabolism and excretion of NO in humans. An experimental and clinical study. Circ. Res. 73:1993;1121-1127.
64. Buga G.M., Griscavage J.M., Rogers N.E., Ignarro L.J. Negative feedback regulation of endothelial cell function by NO. Circ. Res. 73:1993;808-812.
65. Koh K.K., Bui M.N., Hathaway L., Csako G., Waclawiw M.A., Panza J.A., et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am. J. Cardiol. 83:1999;327-331.
66. Koh K.K., Blum A., Hathaway L., Csako G., Waclawiw M., Panza J.A., et al. Effects of estrogen and vitamin E therapies on vascular function in postmenopausal women. Circulation. 100:1999;1851-1857.
67. Cooke J.P., Tsao P.S. Cytoprotective effects of NO. Circulation. 88:1993;2451-2455.
68. Kleinveld H.A., Demacker P.N.M., De Haan A.F.J., Stalenhoff A.F.H. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur. J. Clin. Invest. 23:1993;289-295.
69. Lavy A., Brook G.J., Canker G., Amotz A.B., Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 40:1991;794-799.
70. Giroux L.M., Davignon J., Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta. 1165:1993;335-338.
71. Giroma J., La Ville A.E., Sola R., Plana N., Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am. J. Cardiol. 83:1999;846-851.
72. Palomaki A., Malminiemi K., Malminiemi O., Solakivi T. Effects of lovastatin therapy on susceptibility of LDL to oxidation during α-tocopherol supplementation. Arterioscler. Thromb. Vasc. Biol. 19:1999;1541-1548.
73. Nickenig G., Sachinidis A., Michaelsen F., Bohm M., Seewald S., Vetter H., et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 95:1997;473-478.
74. Nickenig G., Jung O., Strehlow K., Zolk O., Linz W., Scholkens B.A., et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am. J. Physiol. 272:1997;H2701-H2707.
75. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., Bohm M., et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 100:1999;2131-2134.
76. Sposito A.C., Mansur A.P., Coelho O.R., Nicolau J.C., Ramires J.A.F. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am. J. Cardiol. 83:1999;1497-1499.
77. Corsini A., Arnaboldi L., Raiteri M., Quarato P., Faggiotto A., Paoletti R., et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (Bay W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol. Res. 33:1996;56-61.
78. Pentikainen P., Saraheimo M., Schwartz J., et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in human. J. Clin. Pharmacol. 32:1992;136-140.
79. Tse F.L.S., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses of normal volunteers. J. Clin. Pharmacol. 32:1992;630-638.
80. Vallance P., Collier J., Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 349:1997;1391-1392.
81. Scalia R., Appel J.Z. III, Lefer A.M. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit. Arterioscler. Thromb. Vasc. Biol. 18:1998;1093-1100.
82. Pasterkamp G., Schoneveld A.H., van der Wal A.C., Hijnen D.-J., van Wolveren W.J.A., Plomp S., et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler. Thromb. Vasc. Biol. 19:1999;54-58.
83. Weber C., Erl W., Weber K.S.C., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30:1997;1212-1217.
84. Kimura M., Kurose I., Russell J., Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 17:1997;1521-1526.
85. Weber C., Erl W., Weber P.C. Lovastatin induces differentiation of Mono Mac 6 cells. Cell. Biochem. Funct. 13:1995;273-277.
86. Niwa S., Totsuka T., Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int. J. Immunopharmacol. 18:1996;669-675.
87. Draude G., Hrboticky N., Lorenz R.L. The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem. Pharmacol. 57:1999;383-386.
88. Bustos C., Hernandez-Presa M.A., Ortego M., Tunon J., Ortega L., Perez F., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32:1998;2057-2064.
89. Abe Y., El-Masri B., Kimball K.T., Pownall H., Reilly C.F., Osmundsen K., et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler. Thromb. Vasc. Biol. 18:1998;723-731.
90. Rohde L.E., Lee R.T., Rivero J., Jamacochian M., Arroyo L.H., Briggs W., et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 18:1998;1765-1770.
91. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl. J. Med. 333:1995;621-627.
92. Terkeltaub R., Solan J., Barry M. Jr., Santoro D., Bokoch G.M. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J. Leukocyte Biol. 55:1994;749-755.
93. Ridker M.P., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 351:1998;88-92.
94. Strandberg T.E., Vanhanen H., Tikkanen M.J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 353:1999;118-119.
95. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
96. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:1999;230-235.
97. Kempen H.J.M., Vermeer M., de Wit E., Havekes L.M. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Arterioscler. Thromb. 11:1991;146-153.
98. Armstrong M.L., Warner E., Connor W. Regression of coronary atheromatosis in rhesus monkeys. Circ. Res. 27:1970;59-67.
99. Small D.M. Progression and regression of atherosclerotic lesions: insights from lipid physical biochemistry. Arteriosclerosis. 8:1988;103-129.
100. Aikawa M., Rabkin E., Voglic S.J., Shing H., Nagai R., Schoen F., et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ. Res. 83:1998;1015-1026.
101. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 97:1998;2433-2444.
102. Xu X.-P., Meisel S.R., Ong J.M., Kaul S., Cercek B., Rajavashisth T.B., et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 99:1999;993-998.
103. Bellosta S., Canavesi V.M., Pfister P., Fumagalli R., Paoletti R., Bernini F., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1998;1671-1678.
104. Williams J.K., Sukhova G.K., Herrignton D.M., Libby P. Pravastatin has cholesterol lowering independent effects on the artery wall of atherosclerosis monkeys. J. Am. Coll. Cardiol. 31:1998;684-691.